Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France
European Heart Journal Open · 03.11.2026 · 6 (6)
DOI: 10.1093/ehjopen/oeag159 ↗Kurz gefasst
Leitlinie in der Zeitschrift European Heart Journal Open, online erschienen am 25.09.2026. Verfasst von Gaël-Sean Marqueyssat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Toulouse University Hospital, 1 Avenue du Professeur Jean Poulhès, 31400 Toulouse, France. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Toulouse University Hospital, CHU de Toulouse.
Abstract (Originalsprache)
Introduction
In 2021, the European Society of Cardiology updated its guidelines for managing heart failure with reduced left ventricular ejection fraction (HFrEF), recommending a four-drug regimen combining a sodium-glucose cotransporter 2 (SGLT2) inhibitor, a beta-blocker, a mineralocorticoid receptor antagonist, and a renin–angiotensin–aldosterone system inhibitor. This study assessed, 6 months after guideline publication, the exposure of this quadruple therapy in patients newly hospitalized for HFrEF and identified associated factors. Methods and results First-time hospitalizations for HFrEF in France in 2022 were identified using the French National Health Data System. Treatment exposure during the year following discharge was described. Logistic regression was used to assess factors associated with receiving quadruple therapy within 30 days, including socio-demographic characteristics, healthcare utilization, and comorbidities. A total of 22 990 patients were included (65.1% men; mean age 74 years, SD 13.5). At 30 days, 26.3% of patients received quadruple therapy (22.5% at 1 year). Exposure rates were 76% for beta-blockers, 70% for renin–angiotensin–aldosterone system inhibitor, 58% for SGLT2 inhibitors, and 47% for mineralocorticoid receptor antagonists. Advanced age, female sex, and certain comorbidities were associated with a lower likelihood of receiving quadruple therapy, while early follow-up with a general practitioner or cardiologist increased this likelihood.
Discussion
Exposure of quadruple therapy remains limited, with challenges in both initiation and persistence over time. Older age and comorbidities would appear to constitute barriers. Further studies with longer follow-up after guideline publication are needed to assess temporal trends and the impact of strategies aimed at improving care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Toulouse University Hospital, 1 Avenue du Professeur Jean Poulhès, 31400 Toulouse, France.
- BIOETICHS UMR 1295, Center for Epidemiology and Research in POPulation Health (CERPOP), University of Toulouse, 37 Allées Jules Guesde, 31073 Toulouse, France.
- Geriatrics Department, Internal Medicine and Cardiogeriatry Unit, Toulouse University Hospital, Pl. du Dr Joseph Baylac, 31300 Toulouse, France.
- Aging-MAINTAIN Research Team, Center for Epidemiology and Research in POPulation Health (CERPOP), University of Toulouse, 37 Allées Jules Guesde, 31073 Toulouse, France.
ORCID-Profile: Gaël-Sean Marqueyssat, Audrey Dintilhac, Blandine Juillard-Condat
Förderung
- Toulouse University Hospital
- CHU de Toulouse
Zitieren
APA
Marqueyssat, G. S., Dintilhac, A., Toulza, O., Cestac, P., & Juillard-Condat, B. (2026). Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France. European Heart Journal Open, 6(6). https://doi.org/10.1093/ehjopen/oeag159
Vancouver
Marqueyssat GS, Dintilhac A, Toulza O, Cestac P, Juillard-Condat B. Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France. European Heart Journal Open. 2026;6(6). doi:10.1093/ehjopen/oeag159
BibTeX
@article{Marqueyssat2026,
author = {Marqueyssat, Gaël-Sean and Dintilhac, Audrey and Toulza, Olivier and Cestac, Philippe and Juillard-Condat, Blandine},
title = {Exposure to guideline-recommended quadruple therapy after first hospitalization for HFrEF in France},
journal = {European Heart Journal Open},
year = {2026},
volume = {6},
number = {6},
doi = {10.1093/ehjopen/oeag159}
}
EUVIMED